Glucagon-like peptide-1 (GLP-1) receptor agonists (GLP-1RAs) are analogs of human endogenous GLP-1, initially approved for the treatment of T2DM and, subsequently, for the treatment of obesity [6]. This evidence concerns the gene GLP1R and type 2 diabetes mellitus.